Home » Authors » Kim Coghill

Articles by Kim Coghill

With MyVax In Phase III, Genitope Raising $51.8M In Public Offering

May 28, 2004

Syrrx Receives Milestone From Biogen Idec In Target Agreement

May 28, 2004

Crawford Asks For Review Of FDA Consulting Requests

May 24, 2004

Crawford Asks For Review Of FDA Consulting Requests

May 24, 2004

Pharmion Gets 'Full Approval' For Vidaza In MDS Subtypes

May 21, 2004

Pharmion Corp.'s value soared 47.8 percent Thursday after the FDA issued full approval of Vidaza, the firm's orphan drug for myelodysplastic syndromes (MDS). (BioWorld Today)

Pharmion Gets 'Full Approval' For Vidaza In MDS Subtypes

May 21, 2004

Pharmion Corp.'s value soared 47.8 percent Thursday after the FDA issued full approval of Vidaza, the firm's orphan drug for myelodysplastic syndromes (MDS). (BioWorld Today)

Senate Passes BioShield In 99-0 Vote; $5.6B Slated For Industry

May 20, 2004

Senate Passes BioShield In 99-0 Vote; $5.6B Slated For Industry

May 20, 2004

FDA: Critical Path Initiative' Sharpens Drug Development

May 19, 2004

FDA: Critical Path Initiative' Sharpens Drug Development

May 19, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...